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Background
Chronic orofacial pain conditions such as trigeminal neu-
ropathic pain, reflex sympathetic dystrophy of the face,
and temporomandibular pain disorders are debilitating
pain conditions. They are known to respond poorly to
treatment including opioids in human patients. There is a
pressing need to better understand the mechanisms of
these chronic orofacial pain conditions so that new and
effective therapeutic targets can be identify. To achieve
this goal, preclinical animal models that well represent
human chronic orofacial pain conditions are needed. In
the present study we used two preclinical models of
chronic orofacial pain, the chronic constriction nerve
injury of the infraorbital nerve (ION-CCI model) and the
oxaliplatin-induced orofacial pain (oxaliplatin model). We
applied newly developed orofacial operant behavioral
assessment to study orofacial pain and to test effects on
Kv7.2 channel activators in alleviating orofacial pain in
these animals.
Materials and methods
Male Sprague–Dawley rats (300–450 g) were used in this
study. In the ION-CCI model a chronic constriction nerve
injury was created using unilateral ligation of the infraorbi-
tal nerve. For oxoliplatin model of orofacial pain, oxalipla-
tin was administered to rats (i.p.) at 2 mg/kg per day for
five consecutive days. Orofacial pain behaviors in
responses to mechanical and cold stimuli were assessed by
the orofacial operant behavioral assessment method. To
test the effects of Kv7.2 activators in alleviating orofacial
pain in these two preclinical models, retigabine or CF341
was administered to these animals at the doses ranging
from 0.19 to 15 mg.
Results
Rats of both ION-CCI model and oxaliplatin model
showed significant orofacial mechanical allodynia and cold
allodynia/hyperalgesia as examined by using the orofacial
operant assessment method. Retigabine, a classical Kv7.2
channel activator, significantly alleviated orofacial cold
allodynia in both ION-CCI model and oxaliplatin model.
CF341, a newly synthesized Kv7.2 channel activator, also
showed alleviation of the orofacial cold allodynia with effi-
cacy similar to retigabine.
Conclusions
In both ION-CCI model and oxaliplatin model, orofacial
operant behavioral assessment gives quantitative measure-
ments of chronic orofacial pain and therapeutic effects of
Kv7.2 activators. The preclinical models shown in this
work are useful for both mechanistic study and drug
development for chronic orofacial pain.
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